Aferetica
Aferetica Srl is an Italian medical-technology company that distributes CytoSorb blood-purification adsorbers exclusively in Italy and develops the proprietary PerLife organ perfusion platform, serving hospital intensive care units treating sepsis, organ dysfunction, and other critical-care conditions.
- Company typePrivate
- Founded2013
- HeadquartersSan Giovanni In Persiceto, Italy
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Aferetica does
Aferetica Srl is an Italian medical technology company founded in 2013 and headquartered in San Giovanni In Persiceto, Italy. It operates in the critical-care purification-therapy space, distributing and developing medical devices that target hospital intensive care units (ICUs) treating life-threatening conditions such as sepsis, acute kidney injury, and cytokine-driven organ dysfunction.
The company's commercial core is a long-standing exclusive distribution partnership with CytoSorbents Corporation, under which Aferetica distributes CytoSorb blood-purification adsorbers — including the HotSwap-enabled exchange workflow — to Italian ICUs; this partnership has been continuously renewed for more than a decade, most recently at ISICEM 2026 in Brussels (March 2026). Aferetica also develops the proprietary PerLife organ perfusion platform for organ preservation during transplant procedures, and the renewed agreement with CytoSorbents now formally couples continued distribution with co-development of PerLife, positioning the company as both a regional distributor and a product developer in the Italian critical-care market.
Aferetica's business model is predominantly a hardware-sales distribution model: revenue flows from selling CytoSorb adsorber consumables and related devices into Italian ICU channels, supplemented by commercial traction of the in-house PerLife platform. Its customer base is concentrated in Italian hospital ICUs, a single-country, single-vertical segment accessed via direct clinical relationships. Leadership consists of CEO Mauro Atti; the company is privately held (Srl designation) with no disclosed outside investors, no parent company, and no publicly available revenue, funding, or financial disclosures.
Aferetica firmographics
Firmographics- Name
- Aferetica
- Legal name
- Aferetica Srl
- Website
- https://aferetica.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Aferetica Srl is an Italian medical-technology company that distributes CytoSorb blood-purification adsorbers exclusively in Italy and develops the proprietary PerLife organ perfusion platform, serving hospital intensive care units treating sepsis, organ dysfunction, and other critical-care conditions.
- Ownership category
- akta.pro rank
Aferetica industry classification
Industry- Product category
- Medical Devices - Critical Care & Organ Perfusion
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Transplant & Immunosuppression Specialty Pharmaceuticals (HLAIACAJ)
Keywords
Where Aferetica is headquartered
LocationHeadquarters
- HQ city
- San Giovanni In Persiceto
- HQ country
- Italy
- HQ region
- Europe
Markets served
Aferetica business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Distribution of CytoSorb Products: Aferetica serves as the exclusive distribution partner for CytoSorbents Corporation in Italy, distributing CytoSorb adsorber devices used in critical care treatment for ICU patients.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Aferetica product offering
Product offeringCore offering
Aferetica develops the proprietary PerLife organ perfusion platform used for organ preservation and transplant support, and serves as the exclusive Italian distributor of CytoSorbents' CytoSorb hemoperfusion adsorber devices for blood purification in ICU settings. Together these offerings target critical care teams treating cytokine storms, sepsis, acute kidney injury, and other life-threatening conditions requiring blood purification and organ support.
Product overview
Aferetica offers a focused product portfolio centered around its PerLife organ perfusion platform. The company operates primarily in the medical device sector, providing organ preservation technology through its exclusive distribution partnership with CytoSorbents in Italy, a collaboration that has spanned more than a decade. The PerLife platform represents Aferetica's core technology offering in the organ perfusion space.
Differentiator
Problem solved
Functional benefit
Brands
- PerLife: Organ perfusion platform developed by Aferetica, included in the collaboration with CytoSorbents.
Products and services
- PerLife Organ Perfusion Platform Proprietary organ perfusion platform developed by Aferetica for organ preservation and perfusion during transplant procedures, designed for hospital transplant and critical care teams.
- CytoSorb Hemoperfusion Adsorber (Italy distribution) Hemoperfusion adsorber device originally developed by CytoSorbents Corporation and distributed exclusively in Italy by Aferetica for blood purification in ICU patients with cytokine storm, sepsis, acute kidney injury, and other critical illnesses, with HotSwap capability for seamless device exchange.
Quantifiable outcome
- 32.7% ICU mortality rate in COSMOS Registry (n=306 patients)
- +4 more outcomes
Companies that use Aferetica
Customer profileSegments1 record
Ideal customer profiles1 record
Aferetica technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Aferetica partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- CytoSorbents CorporationcoreAferetica Srl maintains an exclusive distribution partnership with CytoSorbents Corporation for CytoSorb adsorber products in Italy. The partnership was renewed at ISICEM 2026 in Brussels, extending a collaboration spanning more than a decade. The agreement includes collaboration on Aferetica's proprietary PerLife organ perfusion platform, representing a bidirectional strategic relationship where Aferetica distributes CytoSorb products while both companies collaborate on the PerLife technology.
Scale indicators1 record
Recent moves3 records
Expansion highlights3 records
Aferetica competitors and assessment
Company assessmentBroad incumbents
- Nikkiso: Diversified medtech with blood purification, dialysis, and critical care products. Overlaps with Aferetica in ICU-focused blood purification and hemoperfusion-adjacent therapies.
- Fresenius Medical Care: Global leader in dialysis and blood purification with critical care and ICU therapies. Overlaps with Aferetica in extracorporeal blood purification for critically ill patients.
- Terumo: Global medical device company with extensive presence in blood component processing, perfusion, and critical care. Overlaps with Aferetica's organ perfusion and ICU therapy focus as a broad incumbent.
- Medtronic: Global medtech with ECMO and mechanical circulatory support products serving the same ICU and critical care prescriber base as Aferetica's hemoperfusion offerings.
- B. Braun: Major medical device and infusion therapy company with critical care, blood purification, and surgical product lines. Provides broader-context competition for Aferetica's ICU customer relationships in Italy and Europe.
Direct peers
- TransMedics: Provider of Organ Care System (OCS) platforms for lung, heart, and liver. Direct peer in the ex-vivo organ perfusion and preservation category relevant to Aferetica's PerLife.
- Spectral Medical: Developer of the Toraymyxin hemoperfusion cartridge for endotoxin removal in septic shock. Direct overlap with Aferetica/CytoSorb in blood purification for critically ill ICU patients.
- XVivo Perfusion: Specialist in organ preservation, including STEEN Solution for lung perfusion. Direct peer to Aferetica in machine perfusion and transplant-related medical devices.
- CytoSorbents Corporation: Developer of the CytoSorb hemoperfusion adsorber that Aferetica distributes in Italy. Direct overlap in product, clinical application (cytokine reduction, critical care), and end customers (ICUs).
- OrganOx: Developer of the metra normothermic liver perfusion device. Direct overlap with Aferetica's PerLife platform in organ preservation and machine perfusion for transplant procedures.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Aferetica social profiles
Digital presenceAferetica financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aferetica leadership team
Management profileNumber of profiles
Profiles1 record
Aferetica funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aferetica M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aferetica
What does Aferetica do?
Aferetica develops the proprietary PerLife organ perfusion platform used for organ preservation and transplant support, and serves as the exclusive Italian distributor of CytoSorbents' CytoSorb hemoperfusion adsorber devices for blood purification in ICU settings. Together these offerings target critical care teams treating cytokine storms, sepsis, acute kidney injury, and other life-threatening conditions requiring blood purification and organ support.
Is Aferetica a public or private company?
Aferetica is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Aferetica founded?
Aferetica was founded in 2013. It employs 11 to 50 people.
Where is Aferetica based?
Aferetica is headquartered in San Giovanni In Persiceto, Italy, in the Europe region.
How does Aferetica make money?
One revenue line is on record: distribution of CytoSorb Products.
Who are Aferetica's main competitors?
Broad incumbents on record are Nikkiso, Fresenius Medical Care, Terumo, Medtronic and B. Braun. Direct peers are TransMedics, Spectral Medical, XVivo Perfusion, CytoSorbents Corporation and OrganOx.
Does Aferetica have an API?
No public API is recorded for Aferetica.
What industry is Aferetica in?
Aferetica's product category is Medical Devices - Critical Care & Organ Perfusion. Its primary akta.pro industry code is HLAIACAJ, Transplant & Immunosuppression Specialty Pharmaceuticals. Its NAICS code is 339113 and its SIC code is 3841.